# Hologic Signs Definitive Agreement to Acquire Spain's Reveal Genomics

> Hologic signed a definitive agreement to acquire Barcelona-based Reveal Genomics, adding the HER2DX breast cancer test to its oncology diagnostics portfolio.

- Published: 2026-10-19T20:08:43+00:00
- Section: Mergers & Acquisitions
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-19/hologic-acquire-reveal-genomics
- Source: [Financial Post](https://financialpost.com/pmn/business-wire-news-releases-pmn/hologic-signs-definitive-agreement-to-acquire-reveal-genomics)

## Key takeaways

- Hologic signed a definitive agreement to acquire Reveal Genomics, a Barcelona-based precision oncology company.
- Reveal Genomics develops the HER2DX test to help optimize therapy for patients with HER2-positive breast cancer.
- Completion of the acquisition is subject to Spanish regulatory approval and other customary closing conditions.

Hologic signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops genomic diagnostic tests for personalized cancer treatment. The [Financial Post](https://financialpost.com/pmn/business-wire-news-releases-pmn/hologic-signs-definitive-agreement-to-acquire-reveal-genomics) published the announcement on October 19, 2026. The price was not disclosed.

## Hologic's Definitive Agreement for Reveal Genomics

[Hologic](https://akta.pro/company-profiles/00009fk/hologic) is a global medical technology company focused on women's health, spanning breast and cervical cancer screening, molecular diagnostics and gynecological procedures, and sells to hospitals, OB/GYNs and laboratories across 36 countries. [Reveal Genomics](https://akta.pro/company-profiles/000ahif/reveal-genomics-s-l) is a biotechnology start-up developing diagnostic tools to define therapeutic options for patients with cancer, using machine learning to reveal new cancer research data.

Reveal Genomics' portfolio includes its HER2DX test, which is designed to help optimize therapy for patients with HER2-positive breast cancer. Hologic said the tests are highly complementary to its existing oncology diagnostics, including the Breast Cancer Index test, a genomic assay used to inform decisions on extended endocrine therapy in women with HR+ early-stage breast cancer.

"Reveal Genomics' portfolio is a strong strategic complement to our existing oncology offering within Diagnostic Solutions and would allow us to support even more women diagnosed with breast cancer," said Vitor Rocha, CEO, Diagnostic Solutions at Hologic.

Patricia Villagrasa-Gonzalez, CEO and co-founder of Reveal Genomics, said: "Joining Hologic gives us the scale and capabilities to accelerate that mission and reach many more patients worldwide."

Completion of the acquisition is subject to Spanish regulatory approval and other customary closing conditions.

## Hologic's Take-Private and Surgical Unit Sale

Hologic was acquired by Blackstone and TPG in an $18.3 billion take-private transaction, with $76 per share in cash plus contingent value rights tied to Breast Health revenue milestones, delisting from Nasdaq in April 2026, according to akta.pro [company records](https://akta.pro/company-data). The same records list annual revenue of $4.1 billion as of 2026 and a global presence across 36 countries. Hologic appointed Joe Almeida, former Chairman and CEO of Baxter International, as CEO succeeding Stephen MacMillan, who retired after more than 12 years leading the company through the close of the take-private transaction.

## Hologic's Earlier 2026 Moves

In July 2026, private equity firms Blackstone and TPG, which completed the take-private acquisition of Hologic in April, were seeking to sell the Hologic Surgical unit for more than $4 billion, working with advisers on the potential transaction, MassDevice reported. That same month, Hologic expanded its CE-IVDR mark for the Aptima HPV Assay in the EU and UK to include self-collected vaginal samples via the Aptima Multitest Specimen Collection Kit, BioSpace reported. Med-tech deal value through H1 2026 reached $5.28 billion, the second-highest total behind 2023's $6.88 billion, a figure that includes licensing agreements, joint ventures and development collaborations, BioWorld reported.

## Companies in this story

- [Hologic company profile](https://akta.pro/company-profiles/00009fk/hologic) · website: http://www.hologic.com
- [REVEAL GENOMICS, S.L. company profile](https://akta.pro/company-profiles/000ahif/reveal-genomics-s-l) · website: https://www.reveal-genomics.com

---
News for Agent · https://newsforagent.com/llms.txt